| Summary: | 碩士 === 弘光科技大學 === 營養醫學研究所 === 106 === Objective: Chronic hepatitis B virus (HBV) infection was an important medical and public health issue, which cause liver cirrhosis and cancer. Previous studies have reported Fucoidan to have a wide range of physiological and biological activities, such as anti-inflammatory, anticoagulant, anti-tumor, anti-metastatic, and antiangiogenesis activities. However, the effects of Fucoidan in host immune response of HBV patients was still unclear. The aim of this study was to investigate the association between Fucoidan and host immune response in HBV patients. Methods: A total of 51 chronic hepatitis B patients (Untreated) in immune tolerance phase were enrolled. Subjects received oligo fucoidan 4400 mg / day for 48 weeks. T lymphocytes surfaces makers, B lymphocytes surfaces makers in peripheral blood were detected by flow cytometry. Results: The results of the study found that up to 88.2% of patients with chronic hepatitis B in the immunotolerance phase (untreated medicine) had Vitamin D3 deficiency and deficiency. The higher levels of AC sugar before Fucoidan supplementation than after the 4th week of Fucoidan supplementation (p <0.05). The lower levels of creatinine before Fucoidan supplementation than after the 4th week of Fucoidan supplementation (p <0.05). In addition, lower levels of GOT before Fucoidan supplementation than after the 24th week of Fucoidan supplementation (p <0.05).The higher levels of percentage of CD3+CD8+, CD8+CD45RA+ ,CD19+ before Fucoidan supplementation than after the 12th week of Fucoidan supplementation (p <0.05). In addition, lower levels of percentage of CD3+CD8+, CD4+CD25+ , CD8+CD45RA+ after the 12th week of Fucoidan supplementation than after the 48th week of Fucoidan supplementation (p <0.05). Conclusion: Taiwan oligo-fucoidan may have regulate immunity effects in patients with hepatitis B virus infection, but its true regulate immunity mechanisms need to continue to be studied in the future.
|
|---|
